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er is supported by a NaSummary Background: The extent to which overdiagnosis occurs in lung cancer
screening programmes has been debated. Overdiagnosis refers to the detection by
screening of cancers that would not have become clinically apparent or symptomatic
before that individual died of other causes.
Methods: A retrospective review of coronial autopsies performed in Victoria
between April 1991 and February 2002 was conducted to determine the rate of
incidental lung cancer in individuals who died of natural causes.
Results: A total of 24,708 autopsy reports were searched electronically. We
estimated that in 56% of these death was from natural causes. Amongst individuals
who died naturally there were 167 cases of lung cancer, 47 of these were incidental
including five carcinoid tumours, three small cell tumours, 11 cases of carcinoma in
situ and 28 invasive nonsmall cell lung cancers. Of the incidental invasive nonsmall
cell lung cancers, 86% were stage I.
Conclusions: Although incidental lung cancer is uncommon, there are some lung
cancers that remain undetected during life and do not contribute to death. TheseElsevier Ltd. All rights reserved.
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R.L. Manser et al.502findings support the hypothesis that some lung cancers detected by screening may
never progress to cause symptoms or death in that individual’s lifetime and
therefore may be overdiagnosed by screening.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Spiral low dose computed tomography (CT) has
emerged in the last decade as a potential screening
tool for lung cancer.1,2 The results of observational
studies are promising. CT is more sensitive than
chest radiography and detects a high proportion of
small, early stage and resectable lung cancers.1–3
On the basis of these preliminary studies, some
experts are already advocating screening in prac-
tice.4 There are several limitations however to
relying on observational studies. In particular,
survival of screened cohorts can be affected by a
number of biases including selection bias, lead-
time bias, length-biased sampling and overdiagno-
sis bias.5,6 Overdiagnosis can occur when screening
leads to the detection of cancers that would not
have become symptomatic or be diagnosed clini-
cally before that individual died of other causes.6
Such cancers have also been referred to as
‘‘pseudodisease’’.5,6
The extent to which overdiagnosis occurs in lung
cancer screening programmes has been debated.6,7
However, overdiagnosis of lung cancer is a potential
source of harm from screening given the morbidity
and mortality associated with lung cancer resec-
tion.8,9 For ethical reasons, it is not possible to
assess the extent to which overdiagnosis occurs
antemortem because once a diagnosis of lung
cancer has been made treatment cannot be with-
held to determine which malignancies progress and
which remain stable. Some insight has been gained
from autopsy studies.10–14 Chan et al. examined the
clinical details of those individuals with ‘‘surprise’’
lung cancer detected only at autopsy but not
suspected during life.10,11,13 Of a total of 15,812
autopsies there were 68 ‘‘surprise’’ lung cancers
detected. In all, but three of these cases, the lung
cancer was described as a ‘‘relatively silent
nonlethal event’’.13 However, Strauss et al. have
argued that some of these lung cancers may have
contributed to the subjects’ death. They point out
that many of the cancers were stage III or IV and
some occurred in individuals who were too ill for
medical evaluation which may have hindered the
antemortem diagnosis of cancer.7,12,13 In another
autopsy series on individuals over 65 years old there
were 47 ‘‘incidental’’ lung cancers detected among
3572 autopsies. However, the stage distribution andfurther clinical details were not described.14 To
examine the frequency and characteristics of
incidental lung cancer we conducted a retrospec-
tive review of lung cancer cases found during
coronial autopsies in the State of Victoria, Austra-
lia. In this way we hope to explore the implications
in relation to overdiagnosis of lung cancer by
screening programs. In this review, cases of
‘‘surprise’’ lung cancer were retrospectively exam-
ined by two-independent investigators to deter-
mine whether the cancer contributed to death.Methods
Study population
In Victoria the Coroners Act 1985 (Vic) requires all
unexplained deaths or deaths due to accident or
injury to be reported to the Coroner.15 Usually an
autopsy will be performed and the Coroner will
investigate the circumstances surrounding the
death before a formal finding is made. The
Victorian Institute of Forensic Medicine (VIFM)
provides medical expertise and pathology services
to the Coroner. Deaths referred to the coroner
include the following: those that are unexpected,
unnatural or violent or resulted directly or indir-
ectly from accident or injury; deaths of people held
in care; those for which a death certificate has not
been completed; those that occur during or as a
result of an anaesthetic and are not due to natural
causes; deaths in persons whose identity is un-
known.15 Many of the autopsies performed by the
coronial service are on individuals for whom a
death certificate was not completed because the
treating doctor was unable or unwilling to do so.
This report focuses on individuals with lung cancer
who died from natural causes and deaths from
accidental injury, homicide, or directly from
complications of medical intervention have been
excluded.Autopsy procedure
The lungs were first examined in situ including
pleural surfaces. The lungs and other major
internal organs were then removed from the body
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minor segmental branches were all opened and
examined. The pulmonary arteries and branches
were also examined. Each lung was then sectioned
from the apex to the base in the coronal plane and
examined visually and by palpation for pathology.
Finer sections of the lung were not routinely taken.
Cause of death was listed in the autopsy report
using standard death certificate coding usually by
the pathologist who performed the autopsy.16
Retrieval and review of records
A computerized search of the autopsy reports on
the VIFM database for the period April 1991 to
February 2002 was conducted. All cases of lung
cancer in individuals who died naturally were then
reviewed by one of the investigators (RM) and
classified according to whether lung cancer was
listed on part I of the death certificate or not.
Records in which lung cancer was not listed on part
I were then reviewed independently by two
investigators (RM and MD) and classified according
to whether the lung cancer caused or contributed
to death. Disagreements were resolved by third
party adjudication (DC). Part I of the death
certificate lists the disease or condition directly
leading to death (Ia) and the antecedent causes
(Ib)–(Ic).16 Part II of the death certificate lists other
significant conditions contributing to the death but
not related to the disease or condition causing it.16
The reports detailing the circumstances surround-
ing the death were also searched to determine
whether the diagnosis of lung cancer had been
suspected or made antemortem. For the purposes
of this report incidental lung cancers are defined as
those that were not diagnosed or reported to be
symptomatic prior to death and were found not to
have contributed to death at autopsy. The VIFM
Ethics Committee approved the study.
Statistical analysis
Statistical analysis was conducted using STATA.17
Ninety-five percent confidence intervals were
calculated for proportions using standard meth-
ods.18 Agreement between investigators classifying
autopsy reports was assessed using the kappa
statistic.19Results
There were 24,708 autopsy reports registered on
the database. This represents approximately 7% ofall deaths occurring during the study period in
Victoria.20–22Characteristics of study population
A total of 3702 autopsy reports were retrieved by
the search. The majority of these were false
positives that contained phrases like ‘no evidence
of lung tumour’. The demographic details of all
individuals on the database could not be accessed
without retrieving each individual autopsy report
from the database. We therefore used the informa-
tion on reports retrieved by the search to describe
the demographic profile of the population. Thirty
percent were female and the median age was 60
years (range; o1–97 years). Of those in whom we
were able to classify the cause of death adequately
(n ¼ 3412), the cause of death was from natural
causes in 56% of cases. Thirty-one percent of those
dying from natural causes were female and the
median age was 67 years, only 5% were aged 38 or
less and the 25th and 75th percentiles were 57 and
76 years, respectively.Lung cancer cases
There were 217 cases of primary lung cancer. In 50
cases the death was from unnatural causes. The
remaining 167 lung cancers were in individuals who
died of natural causes. In 107 of the individuals
with lung cancer that died naturally, the lung
cancer contributed directly to death. In a further
eight individuals lung cancer was known to be
symptomatic prior to death but did not contribute
to death. In the remaining 52 individuals with lung
cancer who died of natural causes the lung cancer
was not listed on part I of the death certificate and
these cases were independently reviewed by two of
the investigators to assess whether the lung cancer
contributed to death. The kappa statistic for inter-
rater agreement was 0.9. Forty-seven cases were
classified as incidental, the cause of death in these
cases are described in Table 1. In the remaining five
cases the lung cancer was found to have contrib-
uted to death, but was not directly related to the
underlying cause of death. In 13 cases of those
classified as incidental, the lung cancer had been
listed on part II of the death certificate. Using the
information summarized above on those autopsy
reports retrieved by the search of the database we
estimate that approximately 13,837 (56% of 24,708)
individuals on the entire database died of natural
causes. The rate of incidental lung cancer in
individuals who died naturally is therefore
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this figure is not adjusted for age.
The median age of individuals with incidental
lung cancer was 72 years (range 49–97) and 34%
were females. A senior pathologist (MD) reviewed
all but one of the cases of invasive carcinoma
(excluding carcinoid tumours) for this study. In two
cases, the reviewing pathologist disagreed with the
original autopsy report of invasive carcinoma and
these were reclassified as carcinoma in situ. After
pathological review, the 47 cases of incidental lung
cancer were classified as follows; five carcinoid
tumours (including one carcinoid tumourlet), three
small cell tumours (all limited stage), 11 cases of
carcinoma in situ and 28 invasive nonsmall cell lung
cancers (NSCLCs). Of the invasive NSCLCs, 24 (86%)
were stage I, two were stage II, one was stage III
and one was stage IV. The histological distribution
was as follows: adenocarcinoma (10); adenosqua-
mous (2); squamous cell carcinoma (11); bronchio-
lo-alveolar cell (3); large cell carcinoma (1) and
clear cell (1).
Characteristics of incidental lung cancers
In three of the cases of carcinoid tumour and 10 of
the cases of carcinoma in situ there was no
macroscopic tumour described. Two of the cases
of adenocarcinoma were identified on microscopic
examination only. A further one was described as
small macroscopically but size was not recorded. In
one case of squamous cell carcinoma an area of
induration was described macroscopically but not
measured. Tumour size (maximum diameter) was
recorded for the remaining 30 incidental cases. The
median tumour size was 3 cm (range 1–10 cm). The
25th and 75th percentiles were 2.25 and 4 cm,
respectively. Most of the tumours described macro-
scopically arose within the lung tissue subpleurally
or peripherally, however, six tumours were endo-
bronchial and two hilar. The two hilar lesions were
both 4 cm and with one exception all endobronchial
tumours were 3 cm or greater in size (range
2–10 cm).
In 22 cases of invasive NSCLC data was available
on the degree of tumour differentiation, 14 cases
were either well or moderately differentiated, and
eight were described as poorly or moderately-to-
poorly differentiated.Discussion
In this retrospective review of coronial autopsies
we found that in individuals who died of naturalcauses 28% of lung cancers detected at autopsy
were incidental. By contrast Chan et al. reported a
rate of 12.4% and Suen et al. 20.5% (in individuals
over the age of 65 years).13,14 Contrary to the study
by McFarlane et al., we found that the majority of
incidental cases were either stage 0 or I. By
examining cause of death systematically in this
study we have attempted to overcome some of the
criticisms of previous autopsy studies of lung
cancer.7 Agreement between investigators classify-
ing the autopsy reports of cases of lung cancer was
very good.19 We can therefore be fairly confident
that those cancers classified as incidental in this
study did not contribute to death. Of note in some
of the cases of lung cancer that we had classified as
incidental, the lung cancer was listed on part II of
the death certificate. However, sometimes diseases
are recorded on this part of the certificate even if
they have not contributed to death as a way of
highlighting the finding.23 For example, in some
reports the lung cancer was described as incidental
by the pathologist but was then recorded on part II
of the certificate.
The characteristics of these incidental lung
cancers are such that many would be detectable
by CT or chest X-ray screening. The smallest
recorded size of incidental lung cancers was 1 cm.
Most of the tumours described macroscopically
arose within the lung tissue subpleurally or periph-
erally and those endobronchial or hilar cancers
which were detected, tended to be large and would
likely have been visible on CT. Whilst some might
argue that cancers measuring up to 10 cm are not
likely to be biologically indolent, amongst inciden-
tal cases we would expect to find some cancers that
might have progressed had the individual not died
of other causes and perhaps some that would have
had a benign natural history regardless. Of the
incidental cases of invasive NSCLC, adenocarcino-
ma and large cell carcinoma (including bronchiolo-
alveolar cell) comprised 50% of cases. CT studies
provide evidence that some adenocarcinomas grow
very slowly with tumour doubling times of up to 4
years. In fact, for tumours with the appearance of a
localized ground glass opacity on CT, the average
doubling time was 2.4 years.24 Amongst individuals
with predominantly symptom-detected stage I lung
cancer, adenocarcinoma has the most favourable
prognosis.25 Sixty-four percent of incidental NSCLCs
were either well or moderately differentiated,
which generally have a better prognosis than poorly
differentiated tumours.25,26
The main limitation of this study is that the study
is retrospective and the population studied may not
be representative of all deaths in the community.
Even though we have focused on deaths due to
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sudden or unexpected or had occurred in indivi-
duals who had not sought regular medical care.
Symptomatic cases may be underrepresented be-
cause deaths in such individuals might be less likely
to be reported to the Coroner. Equally however,
studies that focus on hospital deaths are not
representative of the entire population and this is
the first study to our knowledge to examine lung
cancer rates in deaths occurring out of hospital. 27
Given that the study focuses on a general popula-
tion the results may not be applicable to other
populations such as heavy smokers. However, CT
screening for lung cancer has been applied to the
general population in some studies.28 Another
limitation of this study is that judgements about
whether lung cancer was known antemortem were
based on the reports of the circumstances sur-
rounding the death supplied to the Coroner. In most
cases, a known or suspected diagnosis of lung
cancer would have been described on this report
but it is possible that in some circumstances this
information was omitted.
The question of whether standard autopsy will
detect the true number of incidental lung cancers
in the community may not be adequately assessed
by this study. A further potential limitation is that,
because finer sections of the lung were not
routinely taken, very small lung cancers or micro-
invasive cancer could have been missed. Some
evidence suggests that small nodules detected by
CT may be missed at autopsy.29 Indeed in the
present study the median tumour size of incidental
cancers was 3 cm and the smallest lesion was 1 cm,
however CT can detect cancers as small as 3mm.30
Some experts have argued that the concept of
overdiagnosis for lung cancer is not biologically
plausible because of the biologically virulent
behavior of symptomatic lung cancer. However,
although uncommon, prolonged survival of some
individuals with untreated lung cancer has been
reported.31,32 All other thing being equal, the
prognosis of symptomatic lung cancer may differ
from cancers detected by screening. There are
some limitations to reports which have documented
poor survival of screen detected untreated stage I
lung cancer.33–35 Firstly, drawing conclusions from
these studies assumes that the prognosis of lung
cancer is unaffected by the patient being made
aware of the diagnosis or the diagnostic process.
Secondly, these reports are based on individuals
who were either unfit or refused surgery.33,34 The
possibility of selection bias therefore exists; it is
not clear that those who refuse or are unfit for
surgery are representative of all screen-detected
cases. Thirdly, none of the studies reportedwhether individuals, in whom death was attributed
to lung cancer, underwent postmortem examina-
tions. It is possible that individuals diagnosed with
lung cancer who die of other causes will have their
death attributed to lung cancer erroneously. This
has been termed ‘‘sticking diagnosis bias’’.6 For
example, Sobue et al. reported that 80% of deaths
in individuals with screen-detected untreated lung
cancer were due to lung cancer, however, cause of
death was assessed by retrospective review of
records and causes of death other than lung cancer
were used only when those were clearly identi-
fied.33 Our study highlights the difficulty that could
arise in assigning cause of death in individuals with
lung cancer. Of those 120 individuals with sympto-
matic lung cancer there were eight with symptoms
of lung cancer who died of other causes and of the
remaining 112, 51% had co-morbid conditions that
contributed to death.
Although incidental lung cancer is uncommon,
there are some lung cancers that remain unde-
tected during life and do not contribute to death. It
is not possible to determine from the present study,
whether the incidental lesions detected were
biologically indolent or would have progressed to
cause death had the individuals not died from co-
morbid disease. It is not clear the extent to which
our findings might be extrapolated to screening
programmes that tend to be focused on healthy
individuals, however, amongst individuals with lung
cancer co-morbidity is relatively common.36 Some
experts argue that in any screening programme a
proportion of screen-detected cases will be ‘over-
diagnosed’ simply because of competing mortality.6
Future prospective autopsy studies in smokers, with
finer cuts of the lung might give a more accurate
estimate of the likelihood of overdiagnosis of lung
cancer by CT screening.
The findings of this study support the hypothesis
that some lung cancers detected by screening may
never progress to cause symptoms or death in that
individual’s lifetime. This highlights an important
potential source of harm associated with screen-
ing.6 It has been argued that overdiagnosis of lung
cancer by CT screening could be avoided by
documenting growth of nodules prior to biopsy,
however many of the incidental cancers we
identified would have been referred for immediate
biopsy based on current screening protocols.1,37 As
others have recommended, based on current
evidence, individuals interested in lung cancer
screening would best be advised to take part in
controlled screening trials or at the very least be
adequately informed about the potential risks.38,20
Randomized controlled CT screening studies need
to be designed to take account of overdiagnosis
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been considered the most appropriate outcome
measure for screening trials, all-cause mortality
may be more appropriate because it is not subject
to the bias that may arise in assigning cause of
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